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Abstract 
Fluorescent semiconductor quantum dots (QDs) have attracted tremendous attention over the last 
decade. The superior optical properties of QDs over conventional organic dyes make them attractive 
labels for a wide variety of biomedical applications, whereas their potential toxicity and instability in 
biological environment have puzzled scientific researchers. Much research effort has been devoted to 
surface modification and functionalization of QDs to make them versatile probes for biomedical 
applications, and significant progress has been made over the last several years. This review article aims 
to describe the current state-of-the-art of the synthesis, modification, bioconjugation, and applications of 
QDs for in vivo targeted imaging. In addition, QD-based multifunctional nanoprobes are also summarized. 
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Fluorescent semiconductor quantum dots (QDs) have attracted tremendous attention over the last 
decade. The superior optical properties of QDs over conventional organic dyes make them 
attractive labels for a wide variety of biomedical applications, whereas their potential toxicity 
and instability in biological environment has puzzled scientific researchers. Much research effort 
has been devoted to surface modification and functionalization of QDs to make them versatile 
probes for biomedical applications, and significant progress has been made over the last several 
years. This review article aims to describe the current state-of-the-art of the synthesis, 
modification, bioconjugation, and applications of QDs for in vivo targeted imaging. In addition, 
QD-based multifunctional nanoprobes are also summarized. 
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 Over the last two decades, many imaging tools have been applied in biological and 
biomedical research, such as magnetic resonance imaging (MRI) [1-3], computed tomography 
(CT) [4,5], positron emission tomography (PET) [6-10], single-photon emission computed 
tomography (SPECT) [11], fluorescence/bioluminescence [12-15], ultrasound (US) [16], as well 
as multimodality approaches that can combine the benefit of various imaging techniques [17-20]. 
With the size comparable to biological molecules, but orders of magnitude smaller than human 
cells, nanoparticles (NPs) can offer unprecedented interactions with biomolecules both on the 
surface of and inside the cells which may revolutionize disease diagnosis and treatment. Upon 
incorporation of certain targeting moieties, these NPs can be employed to interrogate specific 
molecular and cellular events in living systems. For molecular imaging applications, a variety of 
NPs including magnetic NPs [21-23], semiconductor quantum dots (QDs) [24-28], carbon 
nanotubes [29-31], gold NPs [32-34], and graphene-based nanomaterials [35-37] have been 
investigated and are expected to play increasingly more important roles in preclinical/clinical 
research in the future. Among these NPs, semiconductor QDs have attracted significant attention 
for optical imaging applications, because of their exceptional properties and many advantages 
over conventional organic dyes [38].  
In general, QDs are semiconductor nanocrystals composed of II-IV (e.g. CdSe and CdTe) or 
III-V (e.g. InP and InAs) groups of elements. At the nanoscale, the band-gap energy in 
semiconductors depends not only on the composition of the elements, but also on the particle 
size [39-42]. Such size dependence, defined as the “quantum confinement effect”, gives rise to 
unique optical and electronic properties of QDs. Previous reports have demonstrated that by 
varying the composition and particle size, QDs with a wide range of absorption and emission 
wavelengths from the visible to the near-infrared (NIR) region can be synthesized [43-45]. A 
number of features make QDs highly attractive for fluorescence imaging, such as wide 
absorption range, narrow and symmetric emission spectra, high quantum yields (QY; up 
to >90%), long fluorescence lifetime (> 10 ns), large effective Stokes shift (> 200 nm), and high 
resistance to photobleaching and chemical degradation [38]. The small size and high QY endow 
QDs with high sensitivity, making them suitable for single molecule tracking. The combination 
of size-tunable fluorescence, large Stokes shifts, and narrow emission spectrum makes it possible 
to separate the fluorescence signals from different QDs for multiplexed imaging. Because of the 
high photostability, QDs have also been widely used for long-term imaging studies [46]. 
Although QDs have many advantages in imaging and spectroscopy, as mentioned above, 
many barriers exist that can hinder the broad use of QDs for bioimaging applications [47]. For 
example, the potential toxicity caused by the release of heavy metal ions remains a major 
concern for QD-based agents [48-50]. In addition, pH-sensitive photoluminescence and 
prolonged retention in animal studies are also undesirable characteristics that need to be 
overcome [51-53]. To address these issues, decorating the surface of QDs with biocompatible 
molecules such as polymers, liposomes, or inorganic silica have been investigated [54-56]. To 
achieve specific targeting, QDs need to be conjugated to targeting ligands such as peptides, 
proteins, nucleotides, among others. For in vivo imaging applications, the following factors need 
to be taken into account when designing the probes: potential toxicity at the effective doses for 
imaging, interference with or from normal biology/physiology, circulation lifetime, optimal 
excitation/emission wavelength for sufficient tissue penetration of signal, chemistry for 
ligand-conjugation and avoiding non-specific trapping, cost effectiveness, etc.  
In this review article, we will summarize the recent progress in the use of QD-based 
nanoprobes for imaging applications, in particular molecularly targeted imaging in animal 
models. First, we will give a brief overview of the synthesis and surface modification strategies 
which can render QDs suitability for biomedical applications. Next, we will discuss in detail the 
use of QD-based agents for in vivo targeted imaging. Various examples of QD-based 
multifunctional nanoprobes for in vivo dual-modality imaging will also be illustrated. Lastly, we 
will discuss the challenges and future directions for applications of QDs in the biomedical arena.  
 
2. SYNTHESIS AND SURFACE MODIFICATION OF QDS 
2.1. Synthesis of QDs 
Since the first report of QD synthesis about three decades ago [39], a variety of synthetic 
methods have been developed for the preparation of QDs. Based on the different media used, 
these methods can be broadly classified into two types: the organometallic route [57-60] and 
aqueous synthesis [61-63]. In a typical organometallic synthesis of QDs, a solvent with high 
boiling point and high coordinating capability to both metal and chalcogen elements is used, 
such as trioctylphosphine oxide (TOPO). QDs synthesized in these organic solvents possess 
nearly perfect crystal structures, and thus high fluorescence QY. Narrow size distribution is 
another advantage for QDs prepared via this route. However, the hydrophobic surface of QDs 
synthesized using this method is a major obstacle for biological applications. Many strategies 
such as ligand-exchange and coating with a water-soluble shell have been adopted to change the 
surface properties of QDs, however at the cost of significant loss in fluorescence signal. Another 
disadvantage of the organometallic route is the costly and laborious synthetic process. 
In contrast, aqueous synthesis, with the advantages of improved simplicity/reproducibility 
and less toxicity, has gradually become a preferred option, despite the lower QY and broader size 
distribution [64,65]. For example, hydrophilic thiol-capped QDs are more suitable for biomedical 
applications because of their higher stability and better compatibility in biological environment 
compared to those prepared in organic solvent. Recently, various methods have been reported for 
the synthesis of thiol-capped QDs, including hydrothermal synthesis, ultrasonic methods, and 
those that use illumination or microwave irradiation [66-69]. 
The composition, size, and shape of QD core are essential to their photoluminescence 
emission range, which can be tuned from visible to the NIR range. In addition, the cores of QDs 
are typically coated with another semiconductor shell composed of materials with lower toxicity 
and wider band-gap (e.g. ZnS) [70,71]. The presence of such a shell can not only improve the 
photoluminescence properties and passivate the surface traps, but also prevent the leaching of the 
highly toxic heavy metal ions from the QDs [72]. 
To date, CdSe/ZnS [25,73-80] and CdTe/ZnS [81-83] QDs are among the most widely 
investigated QDs for in vivo imaging, partly due to their commercial availability and mature 
synthetic procedure. Meanwhile, there are also many studies using CdTe/CdS, CdHgTe, and PbS 
QDs [84-87], which are attractive for in vivo applications because of their NIR emission. To 
avoid the use of Cd, since it is one of the most toxic elements, many groups have reported the 
synthesis and evaluation of InAs/InP/ZnSe [26,88], CuInS2/ZnS [89,90], CuInSe/ZnS [91], and 
silicon QDs [92], which will be discussed in more detail in the following text. Recently, 
photoluminescent carbon-based NPs have also attracted significant attention [93]. Prepared by 
laser ablation or electrochemical oxidation of carbon targets [94,95], these luminescent carbon 
NPs are also subjected to the quantum confinement effects hence are called carbon QDs or 
C-dots. The strong sustained fluorescence of these C-dots in mice, together with their 
biocompatibility and non-toxic features, make C-dots an exciting new class of probes for optical 
imaging [96].  
 
2.2. Surface Modification of QDs 
Surface modification of QDs can improve the aqueous solubility, especially for those 
synthesized via the organometallic route, as well as protect them from degradation and 
fluorescence quenching. In addition, certain surface modification (e.g. with polyethylene glycol 
[PEG]) can also help to reduce non-specific uptake in normal organs and provide functional 
groups for further bioconjugation. 
PEG coating, because of its well-known biocompatibility and mature chemistry, is one of the 
most commonly used strategies for surface modification of QDs. Many literature reports have 
shown that PEG coating can change the biodistribution of QDs in animals [97,98]. For example, 
All-Jamal et al. reported that PEG-lipid coated QDs exhibited much longer blood circulation 
half-life than the unmodified QDs after systemic administration [97]. In another study, it was 
demonstrated that PEGylation can reduce the uptake of QDs into organs of the 
reticuloendothelial system (RES), such as the liver and spleen [98].  
Surface modification of QDs with a combination of PEG and other polymers has also been 
investigated. In an early study, Gao et al. reported the use of an ABC triblock copolymer in 
addition to PEG for QD coating, aiming to minimize the aggregation and fluorescence loss of 
QDs when they are stored in physiological buffer or injected into live animals [25]. Various 
experiments in cells and animal models confirmed the good stability and brightness of these QDs. 
In another report by Zintchenko et al., a new type of quantoplexes incorporating NIR-emitting 
CdTe QDs, polyethylenimine (PEI), and plasmid DNA (pDNA) were assembled [99]. Upon 
intravenous injection, the quantoplexes accumulated rapidly in the lung, liver, and spleen, and 
the fluorescence signal could be detected for at least a week. Tracking of these quantoplexes 
immediately after intravenous injection revealed a rapid redistribution from the lung to the liver, 
which was dependent on the PEI topology and the quantoplex formulation. In addition, a similar 
quantoplex was also assembled where the PEI was replaced by PEG-PEI conjugate, which 
exhibited passive tumor accumulation in nude mice bearing subcutaneous tumors. Using a solid 
dispersion technique, hydrophobic PCDA (10,12-pentacosadiynoic acid) was incorporated to 
assemble QDs-loaded micelles [100]. In this design, both PEG-PCDA and PCDA-Herceptin 
conjugates participated in the micelle assembly, which was subjected to intra-micellar 
cross-linking between PCDAs upon UV irradiation. Non-invasive fluorescent imaging showed 
that with Herceptin as the targeting ligand for human epidermal growth factor receptor 2 (HER2), 
these QD-loaded micelles exhibited high anti-tumor activity and selective toxicity, which led to a 
marked reduction in tumor volume. 
In addition to PEG, other polymeric coatings such as poly (lactic-co-glycolic acid) (PLGA) 
and liposomes have also been explored [84,101,102]. In the report on QD-PLGA assembly, in 
vivo experiments demonstrated the increased stability of QD-entrapped nanospheres, between 
100 and 200 nm in size, against photooxidation and photobleaching [101]. In another report, the 
QD-drug-liposome hybrid was found to exhibit greater uptake in mouse brains and lower uptake 
in the heart and liver compared to free QDs [102]. Recently, an amphiphilic polymer with 
hydrophobic inner core, termed as N-succinyl-N’-octyl nanomicelles (SOC), was used to 
incorporate oil-soluble PbS QDs for subsequent long-term tracking in vivo [84]. 
Inorganic silica is a class of highly biocompatible material that is regularly used as a food 
additive. Encapsulating QDs within silica can provide a hydrophilic surface and facilitate the 
incorporation of various functional groups such as carboxyl, amine, and thiol groups for further 
bioconjugation [103,104]. Furthermore, silica shell can prevent the release of toxic QD 
components into the biological environment [72,105]. Although very few silica-coated QDs have 
been reported for in vivo targeted imaging to date, there are several studies focusing on the 
toxicity and biodistribution assessment. In one report, liver and kidneys were found to be the 
main target organs for silica-coated QDs (QD-SiO2) [106]. It was suggested that QD-SiO2 were 
metabolized via three pathways according to their distinct aggregated states in vivo. A fraction of 
QD-SiO2 kept their original form and could be filtered by glomerular capillaries and excreted via 
urine within five days. Most QD-SiO2, adsorbed onto proteins and aggregated into larger 
particles, were metabolized in the liver and excreted via the feces. Part of the aggregates 
remained in the hepatic tissue for a prolonged time period and could not be readily cleared. 
When compared with commercially available QDs (Invitrogen, CA) of similar size and emission 
wavelength, it was found that QD-SiO2 exhibited a different biodistribution pattern [107].The 
commercially available QDs from Invitrogen showed predominant liver and spleen uptake 
shortly after intravenous injection, whereas QD-SiO2 exhibited much lower liver and spleen 
uptake but higher kidney uptake, blood retention, and partial renal clearance.  
 
2.3. Strategies for Conjugation of QDs with Biomolecules 
To effectively recognize and enable non-invasive imaging of specific molecular targets in 
various organisms, QDs need to be conjugated with ligands that can specifically bind to or 
interact with the target of interest [108,109]. Taking into account the surface properties of QDs 
and the functional groups within the selected targeting ligands, a number of different conjugation 
strategies can be employed. 
Two general approaches can be adopted for QDs with hydrophobic surfaces, which are 
typically prepared via the organometallic route. These QDs need to be first rendered hydrophilic 
through either surface ligand exchange [90,110] or interaction with amphiphilic polymers [111]. 
Subsequent conjugation of biomolecules to the QDs can be achieved during the ligand exchange 
step by introducing thiolated biomolecules, which is quite straightforward to obtain QD 
bioconjugates. However, there are many concerns about the stability and luminescent properties 
of the resulting QD bioconjugates. For those QDs with amphiphilic polymer as the surface cap, a 
step of coupling the biomolecules to the polymer is needed [112]. With hydrophilic surfaces, 
these QDs share similar conjugation strategies with the QDs synthesized via the aqueous route. 
Based on the functional groups on the QD surface, different reactions can be used for surface 
conjugation of QDs (Fig. (1)). 
Ethyl(dimethylaminopropyl) carbodiimide (EDC), one of the most widely used coupling 
reagents for amide bond formation between carboxylic acid and amino groups, has been 
commonly used for surface modification of QDs (Fig. (1A)) [113]. It has also been used to 
produce QD-streptavidin conjugates for subsequent binding of biotinylated molecules [114]. 
However, EDC coupling can cause non-specific crosslinking, since there can be multiple 
carboxylic acid groups and amino groups in a single biomolecule, which may lead to a loss of 
bioactivity especially when the carboxylic acid and/or amino groups are involved in the 
biological function. Compared to EDC coupling, the thiol-maleimide reaction is more specific, 
since typically only the thiol is on the biomolecule but not the maleimide. For example, amino 
groups on the QD surface can be converted to maleimide by reaction with a crosslinker, 
succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), which is then 
conjugated to thiolated peptides, cysteine-tagged proteins, or partially reduced antibodies via the 
thiol-maleimide reaction (Fig. (1B)). 
Another commonly used strategy for functionalization of QDs is through the 
(strept)avidin-biotin interaction, which is attractive because of its high affinity and specificity 
[115-117]. This method relies on either direct binding between streptavidin-functionalized QDs 
with biotinylated proteins/peptides (Fig. (1C)), or the use of avidin as a bridge between 
biotinylated QDs and biomolecules. Metal-histidine binding has also been investigated for 
surface modification of QDs, in which nickel nitrilotriacetic acid (Ni-NTA, a compound widely 
used for isolation and purification of proteins that contain histidine tags) groups were introduced 
[118-120]. For example, QDs can be modified with Ni-NTA groups via EDC coupling, and 
subsequent metal affinity interactions can allowed a stoichiometry-controlled binding of this 
complex to oligohistidine-tagged proteins (Fig. (1D)).  
 Besides the abovementioned strategies, electrostatic interactions have also been used for 
conjugating amine-containing dihydrolipoic acid (DHLA ) derivative -modified QDs with 
hyaluronic acid [121]. In addition, several protein-mediated strategies have been reported for 
bioconjugation of QDs, and one of which involves a commercially available engineered 
haloalkane dehalogenase called the HaloTag protein (HTP) [122,123]. HTP in its native form can 
covalently bind to a synthetic HaloTag ligand (HTL) through the formation of an ester bond 
between the chloroalkane within the HTL and the Asp
106
 residue of the protein, as shown in Fig. 
(2A). A critical mutation in the catalytic triad (His
272
 to Phe) of HTP can cease further hydrolysis 
of the newly formed ester bond between HTP and HTL, thereby leading to permanent linkage of 
the HTL to HTP. In a report by Zhang et al. [124], an engineered Renilla luciferase (Luc8) was 
genetically fused to the N terminus of HTP and expressed to obtain the fusion protein HTP-Luc8. 
After conjugating QDs with a HTL, irreversible covalent binding between the HTL-conjugated 
QDs and HTP-Luc8 led to close proximity of Luc8 and QDs and subsequent bioluminescence 
resonance energy transfer (BRET, Fig. (2A)), which can have many potential applications.  
 In an intriguing report, intein-mediated protein splicing (a process that takes place after 
mRNA has been translated into a protein) was used for surface modification of QDs for 
multiparameter imaging of cellular function [125]. Typically composed of three segments: 
N-extein, intein, and C-extein, intein can also excise itself and rejoin the remaining portions 
(N-extein and C-extein) with a peptide bond. In this study, various proteins were genetically 
tagged with the N-terminal half of a split intein (IN) or the C-terminal half (IC), whereas the 
complementary half of the intein was biotinylated and conjugated to streptavidin-coated QDs 
[125]. Intein-mediated splicing led to simultaneous, site-specific conjugation of QDs to multiple 
protein targets, which opened up new possibilities for bioimaging applications (Fig. (2B)).  
 
3. IN VIVO TARGETED IMAGING WITH QDS 
 Different from passive targeting, which typically depends on the enhanced permeability and 
retention (EPR) effect for accumulation in the tumor [1,126,127], active targeting can be 
achieved by attaching various targeting ligands to QDs for recognition of specific cell surface 
molecules or proteins. A wide variety of targeting ligands have been investigated for in vivo 
targeted imaging with QDs, as we discuss in detail below.  
 
3.1. In Vivo Kinetics of QDs 
 An ideal fluorescence probe for non-invasive in vivo targeted imaging should satisfy several 
requirements, which include sufficiently long circulating lifetime, minimal non-specific uptake 
in the RES, sustained fluorescence within the timeframe of a given study, high biocompatibility 
and low toxicity, among others. A large number of literature reports have indicated that particle 
size and surface coating are both important factors that can affect the in vivo behavior of QDs 
[48,54,98,106,128-131].  
 In an early report, QDs with different surface coatings were investigated with fluorescence 
imaging in living mice [128]. It was found that the circulating lifetime of QDs depends on the 
chain length of the surface PEG coating. When QDs were coated with 5 kDa methoxyl-PEG, the 
circulation half-life was more than 1 h, compared to less than 12 min for QDs with shorter PEG 
coating. In addition, PEG coating also allowed for fluorescence detection of QDs for at least four 
months in vivo after intravenous injection. In a later report, it was found that QDs of different 
sizes have different clearance pattern in mice [129]. As shown in Fig. (3), fluorescence signal 
from QDs of 4.36 nm in diameter was mainly found in the bladder at 4 h after intravenous 
injection. However, at the same time point, QDs of 8.65 nm in diameter accumulated primarily in 
the lung, spleen, and liver, indicating a different excretion pattern (i.e. hepatobiliary). It was 
concluded that to achieve efficient urinary excretion and elimination of QDs, the overall size 
should be strictly controlled under 5.5 nm. Another possibility is to use biodegradable QDs that 
can be broken down into renal clearable components, which may be developed in the future. In 
another study, Praetner et al. provided experimental evidence for faster deposition of 
carboxyl-coated QDs over amine-coated or PEG-coated QDs in various tissues, which might be 
attributed to the interactions between carboxyl-coated QDs and capillary endothelium [132].  
 
3.2. Peptide-Conjugated QDs 
Peptides are desirable targeting ligands for NPs because of their small sizes, hence a large 
number of peptides can be attached to a single NP such as QD to enhance the avidity and 
specificity. Other advantages of peptides include ease of synthesis, low immunogenicity, and 
tolerance to a variety of reaction conditions, among others. The first report on in vivo 
investigation of peptide-conjugated QDs appeared more than a decade ago [73], in which three 
peptides were evaluated for in vivo targeting of CdSe/ZnS QDs. Subsequently, the 
arginine-glycine-aspartate (RGD) peptide has been widely used in QD-based research because of 
its high affinity for integrins αVβ3 and αVβ5 [79,81,88,133,134]. Integrin αVβ3 is overexpressed on 
the surface of angiogenic endothelial cells and certain tumor cells [135,136], which makes it an 
attractive target for QD-based nanoprobes since extravasation is not required to achieve tumor 
contrast. The first in vivo targeted imaging using peptide-conjugated QDs was reported in 2006 
[81]. As shown in Fig. (4), fluorescence signal in the integrin αVβ3-positive U87MG tumors 
could be observed shortly after intravenous injection and peaked at a few hours post-injection, 
indicating effective integrin αVβ3 targeting of RGD-conjugated QD705 (with peak emission at 
705 nm in the NIR range) in living mice. Detailed histological examination of the tumor tissue 
revealed that targeting was vascular integrin αVβ3 specific with little extravasation. Over the last 
several years, many studies from other research groups have also demonstrated that RGD 
peptide-conjugated QDs could exhibit highly specific tumor targeting and reduced accumulation 
in the lung, kidney, and heart in mice models [86,137-140].  
RGD peptides have been conjugated to Cd-free QDs [88,92,140], which have much lower 
potential toxicity and may find broader biomedical applications for future clinical translation. 
For example, PEGylated InAs/InP/ZnSe QDs were conjugated to either RGD or RAD 
(Arg-Ala-Asp) peptides and compared, which showed much higher tumor uptake for 
RGD-conjugated QDs than RAD-conjugated QDs [88]. In another study, RGD peptides were 
conjugated to PEGylated silicon QDs (SiQD), which were successfully used for in vivo tumor 
targeting, sentinel lymph node mapping, and multiplex NIR imaging (Fig. (5)) [92]. Recently, 
InP/ZnS QDs were first coated with biocompatible dendron for a pilot toxicity evaluation in mice 
[140], which had not only low toxicity at the dose tested but also enhanced passive targeting to 
tumors. After conjugation to RGD peptides, significantly higher tumor uptake and longer 
retention at the tumor sites was observed compared to non-targeted dendron-coated QDs. 
 
3.3. Proteins as Targeting Ligands for QDs 
3.3.1. Antibodies 
Antibodies are a class of diverse and widely used specific ligands for targeted imaging and 
therapy. In 2004, Gao et al. reported the conjugation of QDs to a monoclonal antibody 
recognizing the prostate-specific membrane antigen (PSMA) [25], which was investigated for 
active tumor targeting in xenograft-bearing mice. Subsequently, several other antibodies have 
also been conjugated to QDs and tested for tumor targeting in vivo, such as an anti-AFP 
(alpha-fetoprotein) antibody and Herceptin (anti-HER2) [74,100,141]. In a comparison study, the 
AVE-1642 antibody that binds to the insulin-like growth factor 1 reporter (IGF1R, an emerging 
targeting for cancer imaging and therapy [142]) was used as the targeting ligand for both QDs 
and AlexaFluor 680 [143]. Whole-body imaging of tumor-bearing mice indicated much higher 
tumor uptake of AVE-1642-AlexaFluor 680 than the AVE-1642-QD conjugate, which is more 
likely localized to the RES and engulfed by macrophages. 
Mesothelin, a tumor differentiation antigen, is normally expressed on the mesothelial cells 
lining the pleura, peritoneum, and pericardium [144]. Although the biological functions of 
mesothelin remain to be fully elucidated, overexpression of mesothelin has been found in several 
human cancer types such as malignant mesothelioma, pancreatic, ovarian, and lung 
adenocarcinoma. In addition, limited expression of mesothelin in normal tissues makes it highly 
attractive for specific tumor targeting [144]. In one report, CdTe/ZnS QDs were encapsulated 
into carboxylated amphiphilic triblock polymer F127 (F127COOH) micelles, which were 
conjugated to an anti-mesothelin antibody (Me) for tumor targeting in vivo [82]. Non-invasive 
imaging of tumor-bearing mice showed that Me-F127COOH-QD micelles accumulated at the 
pancreatic tumor site soon after intravenous injection (Fig. (6)).  
The epidermal growth factor receptor (EGFR) is another extensively studied transmembrane 
protein, which has a high degree of homology with HER2 [145,146]. Studies have shown that 
~90% of oral squamous cell carcinoma (OSCC) and head and neck squamous cell carcinoma 
(HNSCC) expresses EGFR at a very high level [147,148]. Therefore, anti-EGFR antibodies have 
attracted significant interest for imaging and therapy of OSCC and HNSCC. For example, an 
anti-EGFR monoclonal antibody was conjugated to QD800, which enabled clear in-situ and in 
vivo imaging of HNSCC [149]. An anti-EGFR antibody was conjugated to Au:CdHgTe QD840 
in another study [86], where QD800-RGD and QD820-anti-CEACAM1 (carcinoembryonic 
antigen-related cell adhesion molecule-1) conjugates were also synthesized and used together 
with QD840-anti-EGFR for in vivo tumor targeting in human lung adenocarcinoma xenografts. It 
was demonstrated that all three tumor markers (EGFR, integrin αVβ3, and CEACAM1) could be 
detected simultaneously, after spectral unmixing of the fluorescence signal from the three 
different QD conjugates. 
 
3.3.2. Antibody Fragments 
Although many monoclonal antibodies have been used for QD-based tumor targeting and 
imaging, the relatively large size of antibodies limits the number of ligands that can be attached 
to the surface of each QD. In addition, it may also hamper the penetration into solid tumors, 
which typically have high interstitial pressure. Alternatively, single-chain antibody fragments 
(ScFv), consisting of antibody heavy- and light-chain variable domains connected by a flexible 
peptide linker, is a much smaller targeting ligand than intact antibodies (25 kDa vs. 150 kDa) 
which can maintain high binding affinity and specificity to the antigen [150]. In one report, 
ScFvEGFR was conjugated to either QDs or magnetic iron oxide (IO) NPs for in vivo tumor 
targeting and imaging in an orthotopic pancreatic cancer model [76]. Cytoplasmic localization of 
ScFvEGFR-QDs was observed as fluorescent clusters, suggesting that cellular uptake of 
ScFvEGFR-QDs was likely via receptor-mediated internalization. In addition, markedly reduced 
uptake of ScFvEGFR-QDs was observed in the liver and spleen when compared to mice injected 
with non-targeted QDs.  
The glucose-regulated protein GRP78, a member of the heat shock protein family that plays 
critical roles in cancer cell proliferation and oncogenesis/angiogenesis, has been shown to bind 
Ca
2+
 and serve as an endoplasmic reticulum (ER) stress signaling regulator [151]. Recently, 
ScFvGRP78 was used as targeting ligands for QD conjugation, which exhibited effective 
inhibition of breast tumor growth in a mouse model [152]. c-Met, a receptor tyrosine kinase that 
is strongly associated with cancer cell proliferation, migration, invasion, and tumor angiogenesis, 
has attracted significant attention for targeted cancer therapy [153,154]. In a recent study, an 
anti-c-Met ScFv (Ms20) was conjugated to doxorubicin-loaded PEGylated liposomes (LD) as 
well as QDs [78]. In vivo tumor targeted imaging (with Ms20-QDs) and cancer therapy (with 
Ms20-LD) were both successfully achieved. 
 
3.3.3. Other Proteins 
Many other proteins besides antibodies can have strong affinity to specific targets/receptors, 
such as EGF (i.e. epidermal growth factor) which is the naturally occurring ligand for EGFR 
[146]. In an interesting study, the distribution of EGF-QDs was compared with unconjugated 
QDs through three distinct phases: tumor influx (~3 min), clearance (~60 min), and accumulation 
(1-6 h) [75]. Both QDs and EGF-QDs behaved similarly at ~60 min, with comparable 
non-specific and rapid tumor influx and clearance, followed by an apparent dynamic equilibrium. 
However, EGF-QDs progressively accumulated in the tumors between 1 and 6 h, whereas 
tumoral concentration of non-targeted QDs gradually decreased during this period. At 24 h after 
injection, tumor fluorescence of either QDs or EGF-QDs was minimal and not readily detectable. 
In another report, specific EGFR targeting with 
99m
Tc-labeled, EGF-conjugated QDs was 
reported in a breast cancer model, which allowed for monitoring of EGFR downregulation upon 
therapy [155].  
Successful delivery of imaging agents to the brain is highly important for both diagnosis and 
treatment of central nervous system (CNS) diseases [3,156]. However, the blood-brain barrier 
(BBB), formed by tight junctions within the capillary endothelium, is a major obstacle for 
successful brain imaging. The wheat germ agglutinin (WGA), isolated from Triticum vulgare, 
belongs to the lectin families and can bind specifically to sugar molecules such as 
N-acetyl-D-glucosamine and sialic acid. By specifically recognizing sugar molecules, 
WGA-conjugated QDs were shown to be capable of binding to glycosylated components on cell 
surface [157,158]. After intranasal administration of WGA-QDs into BALB/c mice, WGA was 
reported to enhance the binding of WGA-QDs with nasal mucosa and further improve their 
uptake in the brain, which peaked at a few hours after administration (Fig. (7)). Such brain 
targeting and imaging characteristics of WGA-QDs makes it a promising nanoplatform for future 
imaging of various CNS diseases. 
 
3.4. Other Ligands for In Vivo Targeting of QDs 
 With many advantages including small size, versatile chemistry, ease of synthesis, and lack 
of immunogenicity, aptamers have recently emerged as a new class of targeting ligands for 
molecular imaging and therapy [159,160]. Although aptamers have been conjugated to many 
types of imaging agents such as organic dyes, magnetic NPs, and gold NPs, investigation of 
aptamer-conjugated QDs is mainly in the in vitro setting [161-163]. To the best of our knowledge, 
there is only one literature report on in vivo imaging and therapy of cancer using QD-aptamer 
conjugates [164]. To achieve active ovarian cancer targeting, QDs was conjugated with a DNA 
aptamer specific for MUC1 (mucin 1, a cell surface associated mucin which is overexpressed in 
many cancer types) via EDC coupling. In addition, doxorubicin (DOX, a commonly used 
anti-cancer drug) was attached to QDs via a pH-sensitive hydrazine bond, which is stable in the 
circulation but can be cleaved and release DOX in acidic environment, such as after 
internalization into cancer cells. In vivo imaging experiments revealed significantly higher tumor 
accumulation of the targeted QD conjugate than the non-targeted QDs [164]. 
 The folate receptor (FR), also called folate-binding protein, is a 
glycosylphosphatidylinositol-anchored protein that specifically binds folic acid and 
folate-conjugated molecules. The alpha isoform of FR (FR-α) is found to be overexpressed in 
many epithelial cancers but not highly expressed in normal tissues except the kidneys. Since the 
affinity of FR for folic acid and folate conjugates is relatively high (Kd ~100 pM), FR-α has been 
extensively investigated for tumor targeting [165], including many studies focusing on QDs 
[80,83,85,89,166,167]. For example, folic acid was conjugated to PEG and subsequently 
deposited onto N-acetyl-L-cysteine (NAC)-stabilized CdTeS alloyed QDs, which was 
demonstrated to be capable of tumor targeting in mouse models [167]. Non-Cd-containing 
CuInS2/ZnS QDs with folate-modified N-succinyl-N’-octyl chitosan (FA-SOC) micelles have 
also been reported [89]. It was shown that the oil-soluble QDs could be effectively dispersed in 
water and served as a platform for tumor targeting and imaging (Fig. (8)).  
 Hyaluronic acid (HA, also known as hyaluronan or hyaluronate), an anionic non-sulfated 
glycosaminoglycan that is widely distributed throughout connective, epithelial, and neural tissues, 
has been conjugated to QDs for tumor targeting since HA was shown to be associated with tumor 
angiogenesis and progression [168]. Since HA can specifically bind CD44, a cell-surface 
glycoprotein overexpressed in many tumor types, HA-QDs was found to have not only cancer 
targeting characteristics, but also the capability for imaging lymphatic vessels [121]. In another 
study, carbohydrate capped QDs were prepared by conjugating PEGylated QDs with D-mannose 
or D-galactosamine, which was tested for in vitro imaging and in vivo liver targeting [169]. 
Captopril is a drug for treating hypertension since it can inhibit the activity of 
angiotensin-converting enzyme. The in vivo behavior of captopril-conjugated QDs has been 
investigated after intraperitoneal injection [77]. Strikingly, it could be delivered into the brain via 
systemic circulation, suggesting that it may be a potential platform to break the BBB. Besides the 
above mentioned ligands for QD conjugation, DOX has also been conjugated to QDs for 
targeting alveolar macrophages and inflammation [170].  
 
4. DUAL-MODALITY IMAGING WITH QD-BASED NANOPROBES  
Tremendous advances have been made in many imaging techniques over the last decade, not 
only in the clinical arena but also in preclinical imaging systems. However, no single imaging 
modality is perfect to obtain all the necessary information for a given study. For instance, 
fluorescence imaging faces the challenge of quantification and deep tissue penetration. MRI has 
superb soft tissue contrast and good resolution but suffers from poor sensitivity. Although PET is 
superior in sensitivity, quantitation, and tissue penetration, its resolution is relatively low. 
Combination of multiple imaging techniques using a single probe can potentially overcome these 
disadvantages and provide synergistic information. Many QD-based nanoprobes have been 
designed and evaluated for these applications.  
 
4.1. Fluorescence/MRI 
In an early report, Mulder et al. coated QDs with paramagnetic gadolinium complexes and 
PEGylated lipids to develop a dual-modality probe for both fluorescence imaging and MRI, 
using the RGD peptides as ligands for tumor targeting [171]. However, the dual-modality probe 
was only tested in vitro. Cho et al. reported a multifunctional nanocarrier composed of 
fluorescent QDs, superparamagnetic IO NPs, an anti-PSMA antibody, and chemotherapeutic 
agent paclitaxel [172]. Although a series of experiments confirmed the safety and 
tumor-targeting capability of the nanocarrier, more studies need to be carried out in the future to 
fully realize its potential for dual-modality imaging.  
In 2011, Tan et al. assembled a multimodal system by co-encapsulating IO NPs and QDs in 
NPs composed of poly (lactic acid)-d-α-tocopheryl polyethylene glycol 1000 succinate [173]. 
Without using any targeting ligands, the passive tumor targeting characteristics of the system was 
demonstrated by both MRI and fluorescence imaging. Breast cancer associated antigen 1 
(BRCAA1) is overexpressed in ~65% clinical specimens of gastric cancer tissues as well as 
several gastric cancer cell lines. Wang et al. reported fluorescence imaging and MRI of gastric 
cancer using BRCAA1 as the target [174]. By conjugating fluorescent magnetic NPs with an 
antibody that binds to BRCAA1, gastric cancer targeted imaging was carried out in 
tumor-bearing nude mice.  
Recently, a core/shell nanoprobe was constructed for dual-modality imaging of breast cancer, 
which was composed of an IO NP core and two outside layers of silica shell [175]. CdSe/ZnS 
QDs (with emission peak at 600 nm) and NIR fluorescent CdSeTe/CdS QDs (with emission peak 
at 780 nm) were embedded inside each silica layer to form the dual-modality agent which was 
termed as MQQ-probe. After conjugation with an anti-HER2 antibody, the HER2-MQQ-probe 
was injected into tumor-bearing mice. NIR fluorescence imaging demonstrated enhanced tumor 
specific accumulation of HER2-MQQ-probe than the non-targeted MQQ-probe. Meanwhile, 
MRI provided detailed anatomical structure of the tumor.  
 
4.2. Fluorescence/CT 
X-ray computed tomography (CT) is one of the most reliable and widely used diagnostic 
tools in the clinic, which is fast, three-dimensional (3D), and has high spatial resolution [1,5]. 
Traditional clinical contrast agents for CT are based on iodinated molecules and compounds with 
high X-ray absorption coefficient. However, these contrast agents are typically cleared very 
rapidly from the blood or lymphatic vessels, which is a major disadvantage. Cardiovascular 
disease is a leading cause of death worldwide, and unstable atherosclerotic plaques represent 
important diagnostic targets in clinical settings for improving patient management [176,177]. 
Recently, fluorescent QDs were combined with iodinated molecules to create a dual-modal 
contrast agent, which can potentially confer the advantages of both CT and optical imaging [178]. 
This nanoemulsion platform, composed of a hydrophobic iodinated oil core with QDs embedded 
inside, was demonstrated to have good fluorescence and X-ray absorption abilities both in vitro 
and in vivo, which can be used for targeting macrophages in atherosclerotic plaques. 
 
4.3. Fluorescence/PET 
PET is another widely used imaging technique in cancer diagnosis, staging, and evaluation of 
therapeutic efficacy due to its high sensitivity, good quantitation capability, and superb tissue 
penetration of signal [7,179-182]. In 2007, we reported the first targeted dual-modality 
fluorescence/PET probe based on QDs, where 
64
Cu was used to label QDs through the DOTA 
(1,4,7,10- tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid) chelator and the RGD peptide 
was employed as the targeting ligand [183]. DOTA-QD-RGD exhibited integrin αvβ3-specific 
binding in cell culture and in U87MG tumor-bearing mice, which had significantly higher uptake 




Cu-DOTA-QD were about 4:1 and 1:1, respectively. Excellent 
linear correlation was obtained between the results measured by in vivo PET imaging and those 
measured by ex vivo NIRF imaging or tissue homogenate fluorescence. Histology examination 
revealed that DOTA-QD-RGD targets primarily the tumor vasculature with little extravasation, 
similar as the previous report using RGD-conjugated QDs without 
64
Cu-labeling [81]. 
Subsequently, an analogous dual-modality probe targeting the vascular endothelial growth factor 
receptor (VEGFR) was also developed in a similar fashion, using VEGF as the targeting ligand 
(Fig. (9)) [184]. Again, vascular specific targeting of QDs was observed with little to no 
extravasation.   
 
5. CONCLUSION AND FUTURE PERSPECTIVES 
For imaging purposes, nanotechnology has touched upon every single modality of the 
molecular imaging arena. Among the diverse NPs, QDs are one of the most intensively studied 
which possess many inherent advantages over traditional fluorescent dyes such as significantly 
higher brightness, tunable and narrow emission spectra, and increased photostability. Robust 
chemistry for surface modification and targeting ligand conjugation is of critical importance to 
the potential applications of QDs. Over the last decade, versatile chemistry has been developed 
for synthesis and functionalization of QDs for in vitro and in vivo imaging.  
Despite the remarkable progress over the last 2 decades, many obstacles exist for wide spread 
use of QD-based imaging agents and potential clinical translation. For example, the potential 
toxicity of QDs is still a major concern, due to the chemical composition of toxic elements such 
as Cd, Se, Hg, Pb, As, etc. Although many studies have demonstrated the safety of QDs in 
animal models, their long-term effect needs to be fully elucidated. To avoid these issues, 
researchers have developed and investigated Cd-free QDs such as CuInS2 QDs, Si QDs, C-dots 
etc., which showed promising results as described above. Another way to improve the stability of 
QDs and thereby reducing the potential toxicity is through the use of optimized surface coating. 
It has been demonstrated that various biocompatible polymers can effectively protect QDs from 
degradation in biological environment. However, these coatings can result in significantly 
increased overall size of QDs and can markedly affect the in vivo distribution, excretion, and 
metabolism. Therefore, there is still a need for new surface coating strategies, with which the 
overall size of QD-based nanoprobes can be strictly controlled in addition to effective protection 
of QDs from biological environment. In addition, the current methods used for conjugation of 
targeting ligands to QDs are suboptimal in several aspects such as low efficiency, cross-reactivity, 
and strong dependence on the conditions and materials used. Development of more efficient, 
specific, versatile, and straightforward conjugation strategies is needed in future research. 
One of the key challenges for QD-based imaging agents is (tumor) targeting efficacy. We 
believe that tumor vasculature (instead of tumor cell) targeting should be the best bet for QDs 
since many of the QD-based probes reported in the literature suffered from poor extravasation 
when compared with small molecules or proteins [185,186]. Aside from oncology, QD-based 
agents may also find broad applications in imaging of cardiovascular diseases since the targets 
are immediately accessible upon intravenous injection. The use of molecularly targeted QDs can 
provide multiple advantages over small molecule-based agents, which include stronger signal 
(due to the superb brightness of QDs over fluorescent dyes), enhanced binding affinity and 
specificity to the target (attributed to multivalency with the presence of a large number of 
targeting ligands), etc.  
When using QDs for in vivo targeted imaging, the choice of targeting ligand is very 
important. Among the different classes of specific ligands, peptides/small molecules are more 
desirable when compared with antibodies/proteins since they can keep the overall size small, are 
easier to synthesize, are more stable and resistant to harsh reaction conditions, and can fully take 
advantage of the multivalency effect since more peptides/small molecules can be attached to each 
QD than antibodies/proteins. Furthermore, antibodies, proteins, and antibody fragments typically 
require the use of complicated biological expression systems for their production, and the 
separation of conjugated QDs from antibodies/proteins can be challenging due to their similar size. 
Although DNA/RNA aptamers are also easy to produce/synthesize and can have less interactions 
with proteins in vivo than antibodies/proteins (i.e. lower background signal), the affinity for 
individual target is usually quite low. In theory, QDs are large enough to enable multiple 
targeting ligands on the surface of a single QD to simultaneously bind to multiple targets. 
However, this aspect has been virtually unexplored to date. Targeting multiple different but 
closely-related receptors (e.g. VEGFR and integrin αvβ3) by incorporating different targeting 
ligands on the same QD, with spacers of suitable length, require robust chemistry to minimize 
batch-to-batch difference and improve reproducibility. 
 The emerging field of multimodality imaging with QD-based nanoprobes can allow 
researchers to detect the same NP with multiple imaging techniques. Cross-modality validation is 
critical for providing more accurate and reliable data than with fluorescence imaging alone. 
Although optical imaging can offer high sensitivity (nM level) to complement MRI (mM level) 
and MRI can bypass the signal penetration limitation of optical imaging, the combination of 
optical and MRI is not optimal since neither modality is quantitative. Dual-modality QD-based 
agents that combine PET (which is very sensitive and highly quantitative) and optical imaging 
(which can significantly facilitate ex vivo validation of the in vivo data) should be of particular 
interest for future biomedical applications. For multimodal imaging employing more than two 
techniques, a PET/MRI/optical agent is perhaps the most useful since such a combination 
provides superb sensitivity (PET), quantitation capability (PET), excellent anatomical 
information and soft tissue contrast (MRI), as well as a means for ex vivo validation (optical) 
which itself can also be useful for highly sensitive imaging in certain clinically relevant scenarios 
(e.g. superficial tissue, endoscopy, and intra-operative guidance). 
The bright future of nanomedicine lies partly in multifunctional nanoplatforms which 
combine both therapeutic components and multimodality imaging, often called “theranostics” 
[187-189]. The ultimate goal of theranostic nanomedicine is that NP-based agents can allow for 
efficient, specific in vivo delivery of therapeutic agents (drugs, genes, etc.) without systemic 
toxicity, and the dose delivered as well as the therapeutic efficacy can be accurately measured 
non-invasively over time. Much future research effort will be needed before this can be a clinical 
reality. Continuous multidisciplinary efforts on the development and optimization of such 
nanoplatforms will shed new light on molecular diagnostics and molecular therapy, and newer 
generation of QD-based nanoprobes may have the potential to profoundly impact disease 
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Fig. (1). Representative strategies for bioconjugation of QDs via EDC/NHS coupling (A), 
thiol-maleimide reaction (B), streptavidin-biotin binding (C), and interaction between Ni-NTA 
and histidine (D). 
 
Fig. (2). (A) Modification of QDs through the use of HaloTag protein (HTP) and its ligand 
(HTL). (B) In vivo conjugation of QDs to representative proteins via intein-mediated protein 
splicing. Adapted from [124,125].  
 
Fig. (3). QDs of different sizes exhibited different clearance pattern from mice after intravenous 
injection. (A) Renal clearance of QD515 which has a hydrodynamic diameter of 4.36 nm. (B) 
Poor clearance with high liver and lung uptake for QD574, which has a hydrodynamic diameter 
of 8.65 nm. Bl: bladder; Ki: kidney; Li: liver; Lu: lung; Sp: spleen. Adapted from [129]. 
 
Fig. (4). (A) Scheme for the synthesis of QD705-RGD, in which PEG represents poly (ethylene 
glycol) with molecular weight of 2000. (B) Serial in vivo imaging of U87MG tumor-bearing 
mice after intravenous injection of QD705-RGD (left) or QD705 (right). QD fluorescence is 
color coated red and mouse autofluorescence is color coded green. Arrows indicate tumors. 
Adapted from [81]. 
 
Fig. (5). (A) Scheme for the synthesis and surface functionalization of SiQDs. (B) Tumor 
targeting of RGD-SiQDs and non-targeted SiQDs at 40 h post-injection based on ex vivo imaging. 
(C) Sentinel lymph node imaging captured the fluorescence of SiQDs in an axillary position. 
Red color indicates QD fluorescence and mouse autofluorescence is shown in green. Adapted 
from [92]. 
 
Fig. (6). Me-F127COOH-QD exhibited high tumor targeting efficiency (A) over non-targeted 
F127COOH-QD (C) in a human pancreatic cancer model. B and D are corresponding photos of 
mice in A and C. Me denotes an anti-methoselin antibody. Adapted from [82]. 
 
Fig. (7). (A) Distribution and retention of wheat germ agglutinin-conjugated QDs in the brain 
after intranasal injection into mice. (B) Fluorescence signal in the brain peaks at 4 h after 
injection. Adapted from [157]. 
 
Fig. (8). Schematic illustration of the preparation of fluorescently labeled QD-loaded micelles. 
Adapted from [89]. 
 
Fig. (9). Positron emission tomography (PET) and optical imaging of vascular endothelial 
growth factor (VEGF) receptor expression in a mouse model using a QD-based dual-modality 
probe. 
64
Cu was used as the radiolabel and VEGF was used as the targeting ligand. Adapted from 
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